Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.TORC · Entity 6860 | Chief Commercial Officer | February 27, 2019 | February 28, 2019 |
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date February 27, 2019 · Filed February 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.53 · Expires 2029-02-26 | Direct | 26,000 |
Reported balance
After 2019-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-27 · Grant · Acquired 26,000 · Balance 26,000 F1: 25% of the shares shall vest on February 27, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares shall vest on February 27, 2020, with the remainder vesting in 12 equal quarterly installments thereafter.
Unicycive Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 64,507 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.31 · Expires 2034-01-24 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 91,000 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.17 · Expires 2035-01-21 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Disposition to issuer · Disposed 29,200 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.65 · Expires 2036-01-21 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-18 · Disposition to issuer · Disposed 32,800 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 18, 2026 16:41 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerEmployee Stock Option (Right to buy) · Derivative | 32,800 | Not disclosed Strike: $43.65 | Not disclosed |
DisclosureSEC source: 0001752631-26-000003 · form4-05182026_080528.xml · derivative · entry 4 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,800 shares Expires 2036-01-21 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:41 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerEmployee Stock Option (Right to buy) · Derivative | 29,200 | Not disclosed Strike: $49.17 | Not disclosed |
DisclosureSEC source: 0001752631-26-000003 · form4-05182026_080528.xml · derivative · entry 3 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,200 shares Expires 2035-01-21 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:41 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerEmployee stock option (right to buy) · Derivative | 91,000 | Not disclosed Strike: $46.31 | Not disclosed |
DisclosureSEC source: 0001752631-26-000003 · form4-05182026_080528.xml · derivative · entry 2 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,000 shares Expires 2034-01-24 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:41 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerCommon Stock | 64,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001752631-26-000003 · form4-05182026_080528.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2 · price: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:17 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 558 | $31.72 | $17,699.03 |
DisclosureSEC source: 0001752631-26-000002 · form4-04012026_120401.xml · nonDerivative · entry 3 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,507 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F5 · price: This transaction was executed in multiple trades at prices ranging from $31.64 to $31.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:17 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 2,100 | $31.04 | $65,180.64 |
DisclosureSEC source: 0001752631-26-000002 · form4-04012026_120401.xml · nonDerivative · entry 2 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,065 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F4 · price: This transaction was executed in multiple trades at prices ranging from $30.545 to $31.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:17 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 4,864 | $30.04 | $146,099.97 |
DisclosureSEC source: 0001752631-26-000002 · form4-04012026_120401.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,165 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades at prices ranging from $29.54 to $30.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:06 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 32,800 | $0.00 Strike: $43.65 | $0.00 |
DisclosureSEC source: 0001752631-26-000001 · form4-01232026_110102.xml · derivative · entry 2 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2036-01-21 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:06 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 28,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001752631-26-000001 · form4-01232026_110102.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,029 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:38 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Tax withholdingCommon Stock | 1,922 | $49.95 | $96,003.90 |
DisclosureSEC source: 0001752631-25-000004 · form4-12172025_091225.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,429 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") which vested on December 15, 2025. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 37,000 | $0.00 Strike: $46.31 | $0.00 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · derivative · entry 11 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 37,000 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: One-fourth of the shares subject to the option vest on January 23, 2025 and one-forty-eighth of the shares subject to the option shall vest on each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 37,000 | $67.04 | $2,480,435.60 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 10 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,351 F11 · price: This transaction was executed in multiple trades at prices ranging from $67.00 to $67.271. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Exercise / conversionCommon Stock | 37,000 | $46.31 | $1,713,470.00 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 9 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 34 | $72.64 | $2,469.73 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 8 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,351 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F10 · price: This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 225 | $71.74 | $16,142.24 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 7 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,385 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F9 · price: This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 155 | $70.73 | $10,963.79 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 6 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,610 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F8 · price: This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 1,505 | $69.84 | $105,104.84 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 5 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,765 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F7 · price: This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 2,599 | $68.79 | $178,780.27 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 4 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,270 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F6 · price: This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 1,976 | $67.70 | $133,776.58 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 3 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,869 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F5 · price: This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 1,087 | $66.79 | $72,602.47 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 2 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,845 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F4 · price: This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 19:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 668 | $65.97 | $44,067.36 |
DisclosureSEC source: 0001415889-25-009296 · form4-03312025_110359.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,932 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:28 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 29,200 | $0.00 Strike: $49.17 | $0.00 |
DisclosureSEC source: 0001415889-25-001936 · form4-01232025_090130.xml · derivative · entry 2 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,200 Underlying: Common Stock · 29,200 shares Expires 2035-01-21 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 1, 2025 and 1/48th of the remaining shares subject to the option shall vest on each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:28 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 13,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001936 · form4-01232025_090130.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 1/4th of the RSUs shall vest on each annual anniversary of December 15, 2024, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 09:04 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019812 · form4-07192024_010728.xml · nonDerivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 50% of the RSUs subject to the award shall vest on the NDA Approval Date and 50% of the RSUs subject to the award shall vest on the one year anniversary of the NDA Approval Date, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 17:34 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005278 · doc4.xml · derivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: 25% of the shares shall vest on February 27, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 16:50 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0000899243-18-024668 · doc4.xml · derivative · entry 1 Manning Meredith · CIK 0001752631 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-09-16 F1 · derivative.exercise_date: 25% of the shares shall vest on September 17, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.